BR112016005576A2 - vetores de fator viii de vírus adeno-associado - Google Patents

vetores de fator viii de vírus adeno-associado

Info

Publication number
BR112016005576A2
BR112016005576A2 BR112016005576A BR112016005576A BR112016005576A2 BR 112016005576 A2 BR112016005576 A2 BR 112016005576A2 BR 112016005576 A BR112016005576 A BR 112016005576A BR 112016005576 A BR112016005576 A BR 112016005576A BR 112016005576 A2 BR112016005576 A2 BR 112016005576A2
Authority
BR
Brazil
Prior art keywords
factor viii
adeno
vectors
associated virus
aav
Prior art date
Application number
BR112016005576A
Other languages
English (en)
Other versions
BR112016005576B1 (pt
BR112016005576A8 (pt
Inventor
Nathwani Amit
Tuddenham Edward
Mcintosh Jenny
Cameron Colosi Peter
Original Assignee
Biomarin Pharm Inc
Univ London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51585244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016005576(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharm Inc, Univ London filed Critical Biomarin Pharm Inc
Publication of BR112016005576A2 publication Critical patent/BR112016005576A2/pt
Publication of BR112016005576A8 publication Critical patent/BR112016005576A8/pt
Publication of BR112016005576B1 publication Critical patent/BR112016005576B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14142Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/22Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/008Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo “vetores de fator viii de vírus adeno-associado” a invenção fornece vetores de fator viii (fviii) de vírus adeno-associado (aav) melhorados, incluindo vetores fviii de aav que produzem um polipeptídeo do fator viii funcional e vetores fviii de aav com alta atividade de expressão.
BR112016005576-4A 2013-09-12 2014-09-10 Vetor de fator viii de vírus adeno-associado, partícula de vírus adeno-associado recombinante, partícula viral, uso do referido vetor ou da referida partícula viral para o tratamento de hemofilia a e método para produzir uma partícula de vírus adeno-associado BR112016005576B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361877042P 2013-09-12 2013-09-12
US61/877,042 2013-09-12
PCT/US2014/054960 WO2015038625A1 (en) 2013-09-12 2014-09-10 Adeno-associated virus factor viii vectors

Publications (3)

Publication Number Publication Date
BR112016005576A2 true BR112016005576A2 (pt) 2017-09-12
BR112016005576A8 BR112016005576A8 (pt) 2022-10-18
BR112016005576B1 BR112016005576B1 (pt) 2023-05-30

Family

ID=

Also Published As

Publication number Publication date
HK1226416A1 (zh) 2017-09-29
PH12016500328A1 (en) 2016-05-02
NO2023003I1 (no) 2023-01-12
AR097657A1 (es) 2016-04-06
HUE050484T2 (hu) 2020-12-28
CN105636981B (zh) 2020-11-06
EP3044231A1 (en) 2016-07-20
PL3044231T3 (pl) 2021-01-11
KR20230006058A (ko) 2023-01-10
SG11201601932UA (en) 2016-04-28
JP2019193675A (ja) 2019-11-07
US10463718B2 (en) 2019-11-05
CA2921232C (en) 2023-03-14
NL301222I1 (pt) 2023-03-01
US20200101140A1 (en) 2020-04-02
US20180161403A1 (en) 2018-06-14
US20150071883A1 (en) 2015-03-12
US20170095538A1 (en) 2017-04-06
IL244404B (en) 2021-10-31
HRP20201324T1 (hr) 2020-11-27
TW201546285A (zh) 2015-12-16
JP2016534739A (ja) 2016-11-10
MX2016003262A (es) 2016-09-29
PT3044231T (pt) 2020-08-27
JP6735672B2 (ja) 2020-08-05
AU2014318890B2 (en) 2019-03-07
CA3178384A1 (en) 2015-03-19
LTPA2023508I1 (pt) 2023-04-11
DK3044231T3 (da) 2020-09-07
EP3770169A1 (en) 2021-01-27
MX2021012014A (es) 2021-10-22
ES2813698T8 (es) 2022-01-26
FR23C1007I1 (fr) 2023-03-24
CL2016000502A1 (es) 2016-10-21
CA3178379A1 (en) 2015-03-19
RS61039B1 (sr) 2020-12-31
CY1124213T1 (el) 2022-03-24
KR102484396B1 (ko) 2023-01-04
PE20160769A1 (es) 2016-08-12
RU2019141647A (ru) 2020-01-27
WO2015038625A1 (en) 2015-03-19
IL244404A0 (en) 2016-04-21
FIC20230007I1 (fi) 2023-02-08
NL301222I2 (nl) 2023-10-19
NZ716549A (en) 2022-10-28
TWI632239B (zh) 2018-08-11
KR20160049015A (ko) 2016-05-04
US11406690B2 (en) 2022-08-09
JP2023133597A (ja) 2023-09-22
CN105636981A (zh) 2016-06-01
AU2014318890A1 (en) 2016-02-25
SI3044231T1 (sl) 2020-12-31
HUS2300003I1 (hu) 2023-01-28
US9504762B2 (en) 2016-11-29
RU2019141647A3 (pt) 2020-05-18
US20220339262A1 (en) 2022-10-27
LT3044231T (lt) 2020-11-10
JP2021072871A (ja) 2021-05-13
ES2813698T3 (es) 2021-03-24
RU2710307C2 (ru) 2019-12-26
EP3044231B1 (en) 2020-08-05
RU2016113702A (ru) 2017-10-17
IL286859A (en) 2021-10-31
BR112016005576A8 (pt) 2022-10-18
CA2921232A1 (en) 2015-03-19
CN112538501A (zh) 2021-03-23

Similar Documents

Publication Publication Date Title
MX2021012014A (es) Vectores del factor viii del virus adeno-asociado.
ECSP20015818A (es) Compuesto heterocíclico y su uso
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
PH12018502664A1 (en) Variant adeno-associated viruses and methods of using
TR201901582T4 (tr) Kapsid
BR112015014562A2 (pt) composições pesticidas e processos com estas relacionados
BR112016012358A2 (pt) peptídios terapêuticos
FR3021319B1 (fr) Peptides, compositions les comprenant et utilisations notamment cosmetiques
CO7111285A2 (es) Composiciones pesticidas y procesos relacionados con ellas
CL2015000942A1 (es) Compuestos de benceno sustituido.
BR112016024494A2 (pt) análogos de peptídeo com sonda(s) de aminoácidos ramificados
MX357202B (es) Composicion de particula tipo virus.
BR112015021762A2 (pt) dispositivo de limpeza
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
SG10201803999UA (en) Recombinant factor viii formulations
BR112015024877A2 (pt) vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose
PL403939A1 (pl) Aptamery DNA rozpoznające metkę histydynową oraz ich zastosowanie
BR112018001669A2 (pt) artigo abrasivo com um núcleo que inclui um material compósito
NZ756883A (en) Adeno-associated virus factor viii vectors
Tiwari Padav
দুৱৰা et al. বনফুল
TH75219S1 (th) กางเกงผ้าอ้อม
UA118271U (uk) Інформаційна система
IT201700110269U1 (it) “Forno Bellavista”
UA36118S (uk) Інтерфейс комп'ютерної програми «система обліку газу»

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: BIOMARIN PHARMACEUTICAL INC. (US) ; UNIVERSITY COLLEGE LONDON (GB) ; ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023004648-0 PROTOCOLO 870230021393 EM 13/03/2023 15:54.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/09/2014, OBSERVADAS AS CONDICOES LEGAIS